Genitourinary Cancers Clinical Trials & Research at St. Joseph Health
Medical Group
St. Joseph Health Medical Group is currently enrolling patients for the
following genitourinary cancers clinical trials:
Urothelial Cancer
Prostate Cancer
Renal Cell Cancer
Urothelial
Prevalence of PD-L1 Expression in Patients with Advanced Urothelial Carcinoma (PREVAIL)
Treatment agent: Rucaparib (PARPi)
PI:
Manasa Vulchi, MD
Study Coordinator: Diego
Resources and Links:
clinicaltrials.gov NCT No: NCT03788746
Tucatinib Plus Trastuzumab in Patients with HER2+ Colorectal Cancer
Treatment: Tucatinib + Trastuzumab
PI:
Ian Anderson, MD
Study Coordinator: Kayla
Resources and Links:
clinicaltrials.gov NCT No: NCT03043313
Prostate
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic
Castration-resistant Prostate Cancer Associated with Homologous Recombination
Deficiency (TRITON2)
Treatment agent: Rucaparib (PARPi)
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT02952534
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus
Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant
Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3)
Treatment agent: Rucaparib (PARPi)
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT02975934
Renal Cell
A Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Carcinoma
Treatment: Everolimus
PI:
Ian Anderson, MD
Study Coordinator: Teresa
Resources and Links:
clinicaltrials.gov NCT No: NCT04195750